# Bioequivalence Study of Eltrombopag Olamine Tablets in Healthy Subjects in the Fed State

> **NCT06768619** · NA · COMPLETED · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 36 (actual)

## Conditions studied

- Thrombocytopenia

## Interventions

- **DRUG:** Group 1: single-dose of test formulation+single-dose of reference formulation
- **DRUG:** Group 2: single-dose of reference formulation+single-dose of test formulation

## Key facts

- **NCT ID:** NCT06768619
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-03-20
- **Primary completion:** 2023-04-27
- **Final completion:** 2023-04-27
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2025-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06768619

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06768619, "Bioequivalence Study of Eltrombopag Olamine Tablets in Healthy Subjects in the Fed State". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06768619. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*